{"protocolSection": {"identificationModule": {"nctId": "NCT00117338", "orgStudyIdInfo": {"id": "0476-301"}, "secondaryIdInfos": [{"id": "MK0476-301"}, {"id": "2005_026"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)", "officialTitle": "A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Pediatric Patients (Ages 6 to 14 Years) With Acute Asthma"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-07"}, "primaryCompletionDateStruct": {"date": "2008-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-06-30", "studyFirstSubmitQcDate": "2005-06-30", "studyFirstPostDateStruct": {"date": "2005-07-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-03-16", "resultsFirstSubmitQcDate": "2009-06-26", "resultsFirstPostDateStruct": {"date": "2009-08-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will attempt to find out if the addition of an intravenous form of a drug that is already used for treating asthma in children will help resolve asthma attacks faster than using the current standard care alone.", "detailedDescription": "The duration of treatment is a one time dose."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 276, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Comparator: placebo (unspecified)"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "montelukast sodium", "interventionNames": ["Drug: montelukast sodium"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration", "armGroupLabels": ["2"], "otherNames": ["MK0476", "SINGULAIR\u00ae"]}, {"type": "DRUG", "name": "Comparator: placebo (unspecified)", "description": "Pbo for a study approximately 120 minutes in duration", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After Administration", "description": "Improvement in FEV1 as the time-weighted average change from baseline over 60 minutes following the end of study drug administration. Time-weighted average of the changes from baseline obtained over the 60 minutes (at 60, 45, 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.", "timeFrame": "Baseline and (time weighted average over) 60 Minutes"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Modified Pulmonary Index [mPI] Score", "description": "Change from baseline in modified pulmonary index \\[mPI\\] score assessed 60 minutes following the end of study drug administration. mPI questionnaire scores each component on a scale of 0 to 3 (low to high) with a total possible score of 12.\n\nThe components are respiratory rate, wheezing, prolongation of expiration (Inspiratory:Expiratory ratio), and accessory muscle use.", "timeFrame": "Baseline and 60 minutes"}, {"measure": "Number of Participants With Treatment Failure (Hospitalization or Time to Decision to Discharge > 2 Hours)", "description": "Treatment Failure is defined as a.) patients who required hospitalization, or b.) patients for whom a decision to discharge home has not been reached by 2 hours following the end of study drug administration.", "timeFrame": "120 minutes"}, {"measure": "Time-Weighted Average Change in FEV1 Over 45 Minutes Following the End of Study Drug Administration", "description": "Improvement in FEV1 as time-weighted average change from baseline over 45 minutes following the end of study drug administration: Time-weighted average of the changes from baseline obtained over the 45 minutes (at 45, 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.", "timeFrame": "Baseline and (time-weighed average over) 45 Minutes"}, {"measure": "Time-Weighted Average Change in FEV1 Over 30 Minutes Following the End of Study Drug Administration", "description": "Improvement in FEV1 as the time-weighted average change from baseline over 30 minutes following the end of study drug administration. Time-weighted average of the changes from baseline obtained over the 30 minutes (at 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.", "timeFrame": "Baseline and (time-weighted average over) 30 Minutes"}, {"measure": "Change in FEV1 After 15 Minutes Following the End of Study Drug Administration", "description": "Improvement in FEV1 as the time-weighted average change from baseline over the first 15 minutes following the end of study drug administration. Change = 15 minutes value minus Baseline value", "timeFrame": "Baseline and 15 Minutes"}, {"measure": "Total Dose of \u03b2-agonist Administered Per Patient Over a Period of 2 Hours Following the End of Study Drug Administration", "description": "Median total dose of \u03b2-agonist administered per patient over a period of 2 hours following the end of study drug administration.", "timeFrame": "120 minutes"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Children 6-14 years of age seeking treatment in emergency departments with acute asthma attacks\n\nExclusion Criteria:\n\n* Other respiratory conditions (including congenital lung abnormalities) or other acute illnesses that would complicate current treatment and response for asthma", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "14 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "20306820", "type": "DERIVED", "citation": "Morris CR, Becker AB, Pinieiro A, Massaad R, Green SA, Smugar SS, Gurner DM. A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. Ann Allergy Asthma Immunol. 2010 Feb;104(2):161-71. doi: 10.1016/j.anai.2009.11.065."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Phase III World Wide (U.S., Europe, Asia, South America, and Lithuania) Multicenter Study. Study Start Date: July 2005 Primary Completion Date: March 2008 Study Completion Date: March 2008", "groups": [{"id": "FG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "FG001", "title": "Placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "145"}, {"groupId": "FG001", "numSubjects": "131"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "140"}, {"groupId": "FG001", "numSubjects": "127"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Did not meet Inclusion Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "BG001", "title": "Placebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "145"}, {"groupId": "BG001", "value": "131"}, {"groupId": "BG002", "value": "276"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.2", "spread": "2.36"}, {"groupId": "BG001", "value": "8.9", "spread": "2.32"}, {"groupId": "BG002", "value": "9.1", "spread": "2.34"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "105"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "81"}, {"groupId": "BG002", "value": "171"}]}]}]}, {"title": "Race/Ethnicity", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White (Non-Hispanic)", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "32"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "34"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "112"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}]}, {"title": "Multi-Racial", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "61"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Baseline FEV 1 (L)", "description": "Forced Expiratory Volume in one second, measured in Liters (FEV 1 (L))\n\nA total of 4/276 (1-montelukast; 3-placebo) randomized patients were excluded from the Full Analysis Set (FAS) of the primary endpoint", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.06", "spread": "0.5"}, {"groupId": "BG001", "value": "1.00", "spread": "0.5"}, {"groupId": "BG002", "value": "1.0", "spread": "0.5"}]}]}]}, {"title": "Baseline FEV1 (Percent predicted)", "description": "Percent of predicted baseline Forced Expiratory Volume in one second (FEV1)\n\nA total of 4/276 (1-montelukast; 3-placebo) randomized patients were excluded from the Full Analysis Set (FAS) of the primary endpoint", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.8", "spread": "16.8"}, {"groupId": "BG001", "value": "50.6", "spread": "17.4"}, {"groupId": "BG002", "value": "51.2", "spread": "17.1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After Administration", "description": "Improvement in FEV1 as the time-weighted average change from baseline over 60 minutes following the end of study drug administration. Time-weighted average of the changes from baseline obtained over the 60 minutes (at 60, 45, 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.", "populationDescription": "Full Analysis Set (FAS). The FAS population includes all randomized patients who received double-blind study drug, and with efficacy measurements both at baseline and at least one time point over the time interval considered.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline and (time weighted average over) 60 Minutes", "groups": [{"id": "OG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "OG001", "title": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "lowerLimit": "0.02", "upperLimit": "0.13"}, {"groupId": "OG001", "value": "0.07", "lowerLimit": "0.01", "upperLimit": "1.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.775", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, region (US, non-US) and baseline FEV1 as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.01", "ciPctValue": "95", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.08"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Modified Pulmonary Index [mPI] Score", "description": "Change from baseline in modified pulmonary index \\[mPI\\] score assessed 60 minutes following the end of study drug administration. mPI questionnaire scores each component on a scale of 0 to 3 (low to high) with a total possible score of 12.\n\nThe components are respiratory rate, wheezing, prolongation of expiration (Inspiratory:Expiratory ratio), and accessory muscle use.", "populationDescription": "Full Analysis Set (FAS). The FAS population includes all randomized patients who received double-blind study drug, and with efficacy measurements both at baseline and at least one time point over the time interval considered.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and 60 minutes", "groups": [{"id": "OG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "OG001", "title": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.95", "lowerLimit": "-3.26", "upperLimit": "-2.63"}, {"groupId": "OG001", "value": "-2.96", "lowerLimit": "-3.29", "upperLimit": "-2.63"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.931", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, region (US, non-US) and baseline FEV1 as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.02", "ciPctValue": "95", "ciLowerLimit": "-0.41", "ciUpperLimit": "0.45"}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment Failure (Hospitalization or Time to Decision to Discharge > 2 Hours)", "description": "Treatment Failure is defined as a.) patients who required hospitalization, or b.) patients for whom a decision to discharge home has not been reached by 2 hours following the end of study drug administration.", "populationDescription": "Full Analysis Set (FAS). At least one post-randomization measurement obtained subsequent to at least one dose of study treatment was required for inclusion in the analysis of treatment failure endpoint. Baseline FEV1 measurement was also required to assess this endpoint since it was included in the model.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "120 minutes", "groups": [{"id": "OG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "OG001", "title": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "Hospitalization", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "33"}]}]}, {"title": "Decision to Discharge Home not Reached by 2 Hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.975", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Model terms: treatment and baseline FEV1 as covariate", "paramType": "Odds Ratio (OR)", "paramValue": "0.99", "ciPctValue": "95", "ciLowerLimit": "0.61", "ciUpperLimit": "1.61"}]}, {"type": "SECONDARY", "title": "Time-Weighted Average Change in FEV1 Over 45 Minutes Following the End of Study Drug Administration", "description": "Improvement in FEV1 as time-weighted average change from baseline over 45 minutes following the end of study drug administration: Time-weighted average of the changes from baseline obtained over the 45 minutes (at 45, 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.", "populationDescription": "Full Analysis Set (FAS). The FAS population includes all randomized patients who received double-blind study drug, and with efficacy measurements both at baseline and at least one time point over the time interval considered.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline and (time-weighed average over) 45 Minutes", "groups": [{"id": "OG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "OG001", "title": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "lowerLimit": "0.02", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "0.00", "upperLimit": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.612", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, region (US, non-US) and baseline FEV1 as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.02", "ciPctValue": "95", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.09"}]}, {"type": "SECONDARY", "title": "Time-Weighted Average Change in FEV1 Over 30 Minutes Following the End of Study Drug Administration", "description": "Improvement in FEV1 as the time-weighted average change from baseline over 30 minutes following the end of study drug administration. Time-weighted average of the changes from baseline obtained over the 30 minutes (at 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.", "populationDescription": "Full Analysis Set (FAS). The FAS population includes all randomized patients who received double-blind study drug, and with efficacy measurements both at baseline and at least one time point over the time interval considered.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline and (time-weighted average over) 30 Minutes", "groups": [{"id": "OG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "OG001", "title": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.01", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "-0.00", "upperLimit": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.774", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, region (US, non-US) and baseline FEV1 as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.01", "ciPctValue": "95", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.08"}]}, {"type": "SECONDARY", "title": "Change in FEV1 After 15 Minutes Following the End of Study Drug Administration", "description": "Improvement in FEV1 as the time-weighted average change from baseline over the first 15 minutes following the end of study drug administration. Change = 15 minutes value minus Baseline value", "populationDescription": "Full Analysis Set (FAS). The FAS population includes all randomized patients who received double-blind study drug, and with efficacy measurements both at baseline and at least one time point over the time interval considered.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline and 15 Minutes", "groups": [{"id": "OG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "OG001", "title": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "115"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.01", "upperLimit": "0.10"}, {"groupId": "OG001", "value": "0.01", "lowerLimit": "-0.03", "upperLimit": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.173", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, region (US, non-US) and baseline FEV1 as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.04", "ciPctValue": "95", "ciLowerLimit": "-0.02", "ciUpperLimit": "0.11"}]}, {"type": "SECONDARY", "title": "Total Dose of \u03b2-agonist Administered Per Patient Over a Period of 2 Hours Following the End of Study Drug Administration", "description": "Median total dose of \u03b2-agonist administered per patient over a period of 2 hours following the end of study drug administration.", "populationDescription": "At least one post-randomization measurement obtained subsequent to at least one dose of study treatment was required for inclusion in the analysis of total doses of Beta-Agonist (mg) endpoint.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mg", "timeFrame": "120 minutes", "groups": [{"id": "OG000", "title": "Montelukast Intravenous (IV) 5.25 mg"}, {"id": "OG001", "title": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "lowerLimit": "0.0", "upperLimit": "4.3"}, {"groupId": "OG001", "value": "0.6", "lowerLimit": "0.0", "upperLimit": "3.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.580", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model (Nonparametric) based on Tukey's normalized ranks with terms treatment, region (US, non-US) and baseline FEV1 as covariate", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Montelukast Intravenous (IV) 5.25 mg", "seriousNumAffected": 2, "otherNumAffected": 20}, {"id": "EG001", "title": "Placebo", "seriousNumAffected": 2, "otherNumAffected": 21}], "seriousEvents": [{"term": "Any Infections And Infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Any Injury, Poisoning And Procedural Complications", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Any Respiratory, Thoracic And Mediastinal Disorders", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Asthmatic Crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}], "otherEvents": [{"term": "Any Cardiac Disorders", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Any Gastrointestinal Disorders", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 131}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Gastrooesophageal Reflux Disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 131}]}, {"term": "Any General Disorders And Administration Site Conditions", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Infusion Site Extravasation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Infusion Site Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Any Infections And Infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 131}]}, {"term": "Bronchitis Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 131}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 131}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Any Musculoskeletal And Connective Tissue Disorders", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Muscle Spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Any Nervous System Disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 131}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Syncope Vasovagal", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Any Respiratory, Thoracic And Mediastinal Disorders", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 131}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 131}]}, {"term": "Atelectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 131}]}, {"term": "Rhinitis Allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 131}]}, {"term": "Any Skin And Subcutaneous Tissue Disorders", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 131}]}, {"term": "Prurigo", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Any Vascular Disorders", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}, {"term": "Diastolic Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 131}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Brazil", "Chile", "Colombia", "Costa Rica", "Guatemala", "India", "Lithuania", "Mexico", "Peru", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}